Please login to the form below

Not currently logged in
Email:
Password:

Oscar Ferenczi joins Grünenthal from Sandoz

Will lead German pharma company's Latin American expansion plans

Grünenthal has appointed former region head of Sandoz Latin America Oscar Ferenczi to lead its own Latin America business.

Ferenczi will assume the role of executive VP for Grünenthal Latin America and will also take over as general manger Grünenthal Panama, where the company's regional head office is, and as general manager Grünenthal Latin America, Miami.

He will be based in Miami, Florida, and will report directly to Grünenthal's CEO Dr Harald Stock.

The appointment is a signal of intent for the German pharma company's plans to expand in the emerging Latin America market, which has included the acquisition of Brazilian firm Selfarma and an agreement with US-based Horizon Pharma for the commercialisation of the anti-inflammatory drug Duexis in Latin America.

Ferenczi has years of experience in the market, including nearly four years in his position at Sandoz.

Prior to this period, he spent more than at decade at Merck & Co in the region, including spells as general manager Ecuador, general manager Peru, general manager Chile, and VP and general manager Brazil.

“Strengthening our businesses in Latin America is one of our core strategic objectives as we are aiming to generate 40 percent of Grünenthal's commercial business from the region in 2015,” said CEO Stock.

“I am glad that Oscar has decided to lead the group's strategic business unit with its ambitious, dedicated, and passionate people."

20th February 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics